Howe Jolanda 4

What Happened Jolanda Howe, SVP & Global Controller of Mirum Pharmaceuticals (MIRM), had restricted stock units convert to common shares on Jan 23, 2026 and then sold 842 shares in the open market on Jan 26, 2026. The Jan 23 filing shows 1,500 shares acquired via exercise/conversion of a derivative (related to RSUs) and a simultaneous reported disposition of 1,500 shares at $0 (consistent with shares withheld/settled in connection with vesting). On Jan 26 she sold 842 shares at $96.19 per share, generating $80,994. These transactions appear to be routine vesting and tax-withholding activity rather than a fresh purchase.

Key Details

• Transaction dates and amounts:
  • 2026-01-23: Exercise/conversion of derivative — 1,500 shares acquired (M).
  • 2026-01-23: Derivative disposition — 1,500 shares disposed at $0 (M), reported in connection with RSU settlement/withholding.
  • 2026-01-26: Open-market sale — 842 shares @ $96.19 = $80,994 (S).
• Shares owned after transaction: Not specified in the Form 4 filing.
• Footnotes: F1 = each RSU equals a contingent right to one share (or cash). F2 = shares sold to cover tax withholding on RSU vesting. F3 = RSUs vest 1/3 each year starting 01/23/2024.
• Filing timeliness: Form 4 filed 2026-01-27 covering transactions through 01/26/2026; appears timely.

Context The M-code entries reflect conversion/exercise related to restricted stock units; the zero-dollar disposition and the market sale are consistent with shares being used/ sold to satisfy tax withholding obligations. Tax-withholding sales tied to vesting are common and generally considered routine administrative transactions rather than directional insider bets. The filing does not indicate a 10b5-1 plan or a gift.